John M. McLaughlin, PhD

Sr. Director, Clinical Epidemiology
Pfizer
Collegeville, PA, United States

Dr. McLaughlin is Vice President and Global Medical Lead for Antifectives and COVID-19, Influenza, and mRNA vaccines at Pfizer.

Disclosure(s): Pfizer: Employee, Stocks/Bonds (Public Company)

Presentation(s):

• 88 - Efficacy of nirmatrelvir-ritonavir in high-risk trial participants with prior SARS-CoV-2 infection or vaccination: a pooled analysis

  Thursday, October 17, 2024
  10:42 AM – 10:54 AM US PT